Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from obesity-related complications. The company has a diversified portfolio across ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

Last night’s IT: Welcome to Derry Season 1 finale revealed that the HBO show has been even more intrinsically linked to Andy Muschietti‘s It and IT: Chapter Two than we initially thought. **Spoilers ...

Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices ...

British singer Lily Allen’s appearance as the musical guest on NBC's Saturday Night Live on Saturday night sparked a sharp backlash from some viewers, with social media users questioning her vocals, ...

Lily Allen returned to the Saturday Night Live stage after nearly 19 years away with two performances from her latest pop album, West End Girl. Allen, an SNL musical guest in early 2007, opened with ...

The actress offered exclusive photographs of herself in exchange for donations Desiree Anello is a Writer/Reporter at PEOPLE. She has been working at PEOPLE since 2025. Her work has previously ...

“Believing women’s pain shouldn’t be REVOLUTIONARY,” the actress wrote Lili Reinhart/Instagram Lili Reinhart said she was diagnosed with endometriosis last week She said doctors constantly dismissed ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...

Eli Lilly LLY-0.47%decrease; red down pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

An Eli Lilly drug candidate designed to hit three metabolic targets led patients to lose an average of 28.7% of their body weight in a late-stage clinical trial, setting a new high mark in the ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...